A detailed history of Perennial Investment Advisors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Perennial Investment Advisors, LLC holds 4,708 shares of BMY stock, worth $274,146. This represents 0.03% of its overall portfolio holdings.

Number of Shares
4,708
Holding current value
$274,146
% of portfolio
0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$39.66 - $51.75 $186,719 - $243,639
4,708 New
4,708 $243,000
Q1 2024

May 14, 2024

SELL
$47.98 - $54.4 $48,747 - $55,270
-1,016 Reduced 19.26%
4,260 $231,000
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $872 - $1,041
-18 Reduced 0.34%
5,276 $270,000
Q3 2023

Nov 14, 2023

SELL
$57.89 - $64.73 $3,473 - $3,883
-60 Reduced 1.12%
5,294 $307,000
Q2 2023

Aug 14, 2023

SELL
$63.71 - $70.74 $9,110 - $10,115
-143 Reduced 2.6%
5,354 $342,000
Q1 2023

May 11, 2023

BUY
$65.71 - $74.53 $106,844 - $121,185
1,626 Added 42.0%
5,497 $380,000
Q4 2022

Feb 09, 2023

BUY
$68.48 - $81.09 $30,336 - $35,922
443 Added 12.92%
3,871 $278,000
Q3 2022

Nov 09, 2022

BUY
$0.13 - $76.84 $445 - $263,407
3,428 New
3,428 $244,000
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $219,561 - $255,956
-4,094 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $44,495 - $52,121
752 Added 22.5%
4,094 $241,000
Q2 2021

Jul 29, 2021

SELL
$61.91 - $67.42 $4,828 - $5,258
-78 Reduced 2.28%
3,342 $223,000
Q1 2021

Apr 29, 2021

SELL
$59.34 - $66.74 $29,313 - $32,969
-494 Reduced 12.62%
3,420 $216,000
Q4 2020

Jan 22, 2021

SELL
$57.74 - $65.43 $26,560 - $30,097
-460 Reduced 10.52%
3,914 $243,000
Q3 2020

Oct 26, 2020

BUY
$57.43 - $63.64 $251,198 - $278,361
4,374 New
4,374 $264,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Perennial Investment Advisors, LLC Portfolio

Follow Perennial Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perennial Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perennial Investment Advisors, LLC with notifications on news.